TC
TMO icon

Trilogy Capital’s Thermo Fisher Scientific TMO Stock Holding History

Trilogy Capital’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$506K Sell
1,010
-169
-14% -$81.1K 0.02% 267
2026
Q1 		$580K Sell
1,179
-150
-11% -$81.4K 0.03% 243
2025
Q4 		$770K Sell
1,329
-19
-1% -$10.7K 0.03% 209
2025
Q3 		$654K Buy
1,348
+16
+1% +$7.45K 0.03% 218
2025
Q2 		$540K Sell
1,332
-176
-12% -$73.6K 0.03% 227
2025
Q1 		$750K Buy
1,508
+6
+0.4% +$3.25K 0.04% 187
2024
Q4 		$781K Sell
1,502
-2
-0.1% -$1.1K 0.04% 188
2024
Q3 		$930K Sell
1,504
-44
-3% -$26K 0.05% 176
2024
Q2 		$856K Buy
1,548
+1,046
+208% +$599K 0.05% 175
2024
Q1 		$292K Buy
502
+57
+13% +$32K 0.02% 256
2023
Q4 		$236K Sell
445
-15
-3% -$7.26K 0.01% 240
2023
Q3 		$233K Buy
460
+16
+4% +$8.53K 0.02% 241
2023
Q2 		$250K Buy
444
+24
+6% +$13K 0.02% 251
2023
Q1 		$242K Sell
420
-25
-6% -$14.1K 0.02% 231
2022
Q4 		$245K Buy
445
+44
+11% +$23.3K 0.02% 232
2022
Q3 		$203K Buy
+401
New +$224K 0.02% 174
2018
Q4 		– Sell
-16
Closed -$4K – 519
2018
Q3 		$4K Hold
16
– – ﹤0.01% 437
2018
Q2 		$3K Hold
16
– – ﹤0.01% 427
2018
Q1 		$3K Buy
+16
New +$3.36K ﹤0.01% 360

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Trilogy Capital's TMO Position: Q2 2026 in Review

Trilogy Capital reduced its Thermo Fisher Scientific (TMO) stake by 14% in Q2 2026, selling an estimated $81.1K and leaving 1,010 shares worth $506K. The position accounts for 0.02% of the portfolio, ranked #267.

Trilogy Capital first reported a position in TMO in Q1 2018 and has held it in 19 quarters since. The position peaked at $930K in Q3 2024. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Trilogy Capital held 1,010 shares of Thermo Fisher Scientific worth $506K as of Q2 2026.
  • Trilogy Capital sold 169 Thermo Fisher Scientific shares in Q2 2026, an estimated $81.1K.
  • Thermo Fisher Scientific made up 0.02% of Trilogy Capital's portfolio in Q2 2026, its #267 holding.
  • Trilogy Capital first reported a position in Thermo Fisher Scientific in Q1 2018 and has held it in 19 quarters since.
  • Trilogy Capital's Thermo Fisher Scientific position peaked at $930K in Q3 2024.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.